Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Clinical trial NCT05854849 · RECRUITING
Trial details
- NCT number
- NCT05854849
- Sponsor
- Sun Yat-sen University
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-01
- Primary completion
- 2025-12-01
- Enrollment
- 244
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.